References
- Fonseca R, Bergsagel PL, Drach J, . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
- Chang H, Qi X, Trieu Y, . Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135:486–491.
- Chang H, Ning Y, Qi X, . Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007;139:51–54.
- Shaughnessy JD Jr, Zhan F, Burington BE, . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
- Fonseca R, Van Wier SA, Chng WJ, . Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034–2040.
- Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
- Hanamura I, Stewart JP, Huang Y, . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–1732.
- Ahmann GJ, Jalal SM, Juneau AL, . A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998;101:7–11.
- Chang H, Jiang N, Jiang H, . CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica 2010;95:1542–1547.
- Chang H, Jiang A, Qi C, . Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010;51:2084–2091.
- Klein U, Jauch A, Hielscher T, . Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011;117:2136–2144.
- Chang H, Trieu Y, Qi X, . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779–782.
- Chang H, Trieu Y, Qi X, . Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res 2011;35:95–98.
- Nemec P, Zemanova Z, Kuglik P, . Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2011 Dec 13. [Epub ahead of print]
- Boyd KD, Ross FM, Chiecchio L, . A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349–355.